Pub Date : 2002-06-01DOI: 10.1089/15246090260137635
E. Freeman, Sami Jabara, S. Sondheimer, R. Auletto
OBJECTIVES Evidence shows that the selective serotonin reuptake inhibitors (SSRIs) effectively reduce the symptoms of severe premenstrual syndrome (PMS). A placebo-controlled study of citalopram, the most selective SSRI, demonstrated that half-cycle dosing (luteal phase) was effective for DSM-IV-defined premenstrual dysphoric disorder (PMDD), a severe form of PMS. This study examined the effectiveness of half-cycle dosing of citalopram in PMS patients who did not respond to previous SSRI treatment. METHODS Seventeen women with no improvement in symptoms after two menstrual cycles on an SSRI were given open-label citalopram (20-40 mg/day). Eleven subjects received half-cycle dosing, and 6 subjects received full-cycle dosing. Scores on the 17-item daily symptom report (DSR) and on each of five DSR symptom clusters were used to measure citalopram efficacy. RESULTS Total premenstrual DSR scores were significantly improved (p <0.001) in both half-cycle and full-cycle dosing groups. The half-cycle group reported lower DSR scores throughout treatment compared with the full-cycle group, but the difference did not reach statistical significance in this small sample. All DSR factor scores (mood, behavioral, pain, physical symptoms, and appetite) significantly improved. Clinical improvement (>or=50% decrease from baseline DSR) was reported by 76% of the subjects overall. Forty-one percent of the subjects experienced symptom remission, defined as a decrease in symptoms to postmenstrual levels. CONCLUSIONS These results from a small number of subjects with open-label treatment must be viewed as preliminary but suggest that citalopram treatment is effective for PMS patients who failed previous SSRI treatment.
{"title":"Citalopram in PMS patients with prior SSRI treatment failure: a preliminary study.","authors":"E. Freeman, Sami Jabara, S. Sondheimer, R. Auletto","doi":"10.1089/15246090260137635","DOIUrl":"https://doi.org/10.1089/15246090260137635","url":null,"abstract":"OBJECTIVES\u0000Evidence shows that the selective serotonin reuptake inhibitors (SSRIs) effectively reduce the symptoms of severe premenstrual syndrome (PMS). A placebo-controlled study of citalopram, the most selective SSRI, demonstrated that half-cycle dosing (luteal phase) was effective for DSM-IV-defined premenstrual dysphoric disorder (PMDD), a severe form of PMS. This study examined the effectiveness of half-cycle dosing of citalopram in PMS patients who did not respond to previous SSRI treatment.\u0000\u0000\u0000METHODS\u0000Seventeen women with no improvement in symptoms after two menstrual cycles on an SSRI were given open-label citalopram (20-40 mg/day). Eleven subjects received half-cycle dosing, and 6 subjects received full-cycle dosing. Scores on the 17-item daily symptom report (DSR) and on each of five DSR symptom clusters were used to measure citalopram efficacy.\u0000\u0000\u0000RESULTS\u0000Total premenstrual DSR scores were significantly improved (p <0.001) in both half-cycle and full-cycle dosing groups. The half-cycle group reported lower DSR scores throughout treatment compared with the full-cycle group, but the difference did not reach statistical significance in this small sample. All DSR factor scores (mood, behavioral, pain, physical symptoms, and appetite) significantly improved. Clinical improvement (>or=50% decrease from baseline DSR) was reported by 76% of the subjects overall. Forty-one percent of the subjects experienced symptom remission, defined as a decrease in symptoms to postmenstrual levels.\u0000\u0000\u0000CONCLUSIONS\u0000These results from a small number of subjects with open-label treatment must be viewed as preliminary but suggest that citalopram treatment is effective for PMS patients who failed previous SSRI treatment.","PeriodicalId":80044,"journal":{"name":"Journal of women's health & gender-based medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85126684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-06-01DOI: 10.1089/15246090260137581
J. G. Meisler
{"title":"Toward optimal health: the experts discuss attention deficit disorder.","authors":"J. G. Meisler","doi":"10.1089/15246090260137581","DOIUrl":"https://doi.org/10.1089/15246090260137581","url":null,"abstract":"","PeriodicalId":80044,"journal":{"name":"Journal of women's health & gender-based medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90568943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-06-01DOI: 10.1089/15246090260137626
Lynnelle K. Smith, Jennifer L. Lelas, D. Kerrigan
OBJECTIVES A general perception that women and men walk differently has yet to be supported by quantitative walking (gait) studies, which have found more similarities than differences. Never previously examined, however, are pelvic and center of mass (COM) motions. We hypothesize the presence of gender differences in both pelvic obliquity (motion of the pelvis in the coronal plane) and vertical COM displacement. Quantifiable differences may have clinical as well as biomechanical importance. METHODS We tested 120 subjects separated into four groups by age and gender. Pelvic motions and COM displacements were recorded using a 3-D motion analysis system and averaged over three walking trials at comfortable walking speed. Data were plotted, and temporal values, pelvic angle ranges, and COM displacements normalized for leg length were quantitatively compared among groups. RESULTS Comparing all women to all men, women exhibited significantly more pelvic obliquity range (mean ISD): 9.4 +/- 3.5 degrees for women and 7.4 +/- 3.4 degrees for men (p = 0.0024), and less vertical COM displacement: 3.7 +/- 0.8% of leg length for women and 3.3 +/- 0.9% for men (p = 0.0056). CONCLUSIONS Stereotypically based gender differences were documented with greater pelvic obliquity and less vertical COM displacement in women compared with men. It is unclear if these differences are the intrinsic result of gender vs. social or cultural effects. It is possible that women use greater pelvic motion in the coronal plane to reduce their vertical COM displacement and, thus, conserve energy during walking. An increase in pelvic obliquity motion may be advantageous from an energy standpoint, but it is also associated with increased lumbosacral motion, which may be maladaptive with respect to the etiology and progression of low back pain.
{"title":"Gender differences in pelvic motions and center of mass displacement during walking: stereotypes quantified.","authors":"Lynnelle K. Smith, Jennifer L. Lelas, D. Kerrigan","doi":"10.1089/15246090260137626","DOIUrl":"https://doi.org/10.1089/15246090260137626","url":null,"abstract":"OBJECTIVES\u0000A general perception that women and men walk differently has yet to be supported by quantitative walking (gait) studies, which have found more similarities than differences. Never previously examined, however, are pelvic and center of mass (COM) motions. We hypothesize the presence of gender differences in both pelvic obliquity (motion of the pelvis in the coronal plane) and vertical COM displacement. Quantifiable differences may have clinical as well as biomechanical importance.\u0000\u0000\u0000METHODS\u0000We tested 120 subjects separated into four groups by age and gender. Pelvic motions and COM displacements were recorded using a 3-D motion analysis system and averaged over three walking trials at comfortable walking speed. Data were plotted, and temporal values, pelvic angle ranges, and COM displacements normalized for leg length were quantitatively compared among groups.\u0000\u0000\u0000RESULTS\u0000Comparing all women to all men, women exhibited significantly more pelvic obliquity range (mean ISD): 9.4 +/- 3.5 degrees for women and 7.4 +/- 3.4 degrees for men (p = 0.0024), and less vertical COM displacement: 3.7 +/- 0.8% of leg length for women and 3.3 +/- 0.9% for men (p = 0.0056).\u0000\u0000\u0000CONCLUSIONS\u0000Stereotypically based gender differences were documented with greater pelvic obliquity and less vertical COM displacement in women compared with men. It is unclear if these differences are the intrinsic result of gender vs. social or cultural effects. It is possible that women use greater pelvic motion in the coronal plane to reduce their vertical COM displacement and, thus, conserve energy during walking. An increase in pelvic obliquity motion may be advantageous from an energy standpoint, but it is also associated with increased lumbosacral motion, which may be maladaptive with respect to the etiology and progression of low back pain.","PeriodicalId":80044,"journal":{"name":"Journal of women's health & gender-based medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91104264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-06-01DOI: 10.1089/15246090260137653
P. Greenberger
{"title":"Women's health research: women's health funding for 2003.","authors":"P. Greenberger","doi":"10.1089/15246090260137653","DOIUrl":"https://doi.org/10.1089/15246090260137653","url":null,"abstract":"","PeriodicalId":80044,"journal":{"name":"Journal of women's health & gender-based medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77221207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-06-01DOI: 10.1089/15246090260137590
L. Mosca
OBJECTIVE The objective of this paper is to review prospective, large-scale studies of lipid-lowering therapy and hormone replacement therapy, and to provide clinical recommendations for the management of hyperlipidemia in women within the context of the revised National Cholesterol Education Program (NCEP) guidelines. METHODS Recent English language literature derived from a MEDLINE search (January 1990-July 2001) and bibliographies of relevant papers were reviewed, and data were abstracted from identified papers. RESULTS Hyperlipidemia is largely undertreated in women. Previously, hormone replacement therapy (HRT) was considered first-line treatment for the management of hypercholesterolemia to prevent coronary artery disease (CAD) in women. Recent studies, however, show no benefit of HRT for secondary prevention of coronary events, despite its beneficial effects on lipids. Large-scale, controlled clinical trials indicate that women, even those with only moderately elevated cholesterol, benefit from the lipid-lowering effects of statins for both high-risk primary and secondary prevention of CAD. Based on this evidence, the recently revised NCEP guidelines recommend statins as first-line therapy for women with hyperlipidemia, an approach that is supported by the American Heart Association and the American College of Cardiology. With its emphasis on aggressive intervention for persons with multiple risk factors, the new guidelines substantially increase the number of women eligible for pharmacological therapy. CONCLUSIONS All women with hyperlipidemia should receive counseling regarding lifestyle approaches for lowering cholesterol. The decision to use HRT should be made in the context of other conditions hormones may affect. Alternative hormonal regimens for lipid management may include selective estrogen receptor modulators and phytoestrogens, but results of randomized clinical trials are necessary before firm recommendations can be made regarding their clinical value in preventing CAD.
{"title":"Contemporary management of hyperlipidemia in women.","authors":"L. Mosca","doi":"10.1089/15246090260137590","DOIUrl":"https://doi.org/10.1089/15246090260137590","url":null,"abstract":"OBJECTIVE\u0000The objective of this paper is to review prospective, large-scale studies of lipid-lowering therapy and hormone replacement therapy, and to provide clinical recommendations for the management of hyperlipidemia in women within the context of the revised National Cholesterol Education Program (NCEP) guidelines.\u0000\u0000\u0000METHODS\u0000Recent English language literature derived from a MEDLINE search (January 1990-July 2001) and bibliographies of relevant papers were reviewed, and data were abstracted from identified papers.\u0000\u0000\u0000RESULTS\u0000Hyperlipidemia is largely undertreated in women. Previously, hormone replacement therapy (HRT) was considered first-line treatment for the management of hypercholesterolemia to prevent coronary artery disease (CAD) in women. Recent studies, however, show no benefit of HRT for secondary prevention of coronary events, despite its beneficial effects on lipids. Large-scale, controlled clinical trials indicate that women, even those with only moderately elevated cholesterol, benefit from the lipid-lowering effects of statins for both high-risk primary and secondary prevention of CAD. Based on this evidence, the recently revised NCEP guidelines recommend statins as first-line therapy for women with hyperlipidemia, an approach that is supported by the American Heart Association and the American College of Cardiology. With its emphasis on aggressive intervention for persons with multiple risk factors, the new guidelines substantially increase the number of women eligible for pharmacological therapy.\u0000\u0000\u0000CONCLUSIONS\u0000All women with hyperlipidemia should receive counseling regarding lifestyle approaches for lowering cholesterol. The decision to use HRT should be made in the context of other conditions hormones may affect. Alternative hormonal regimens for lipid management may include selective estrogen receptor modulators and phytoestrogens, but results of randomized clinical trials are necessary before firm recommendations can be made regarding their clinical value in preventing CAD.","PeriodicalId":80044,"journal":{"name":"Journal of women's health & gender-based medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83928300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-06-01DOI: 10.1089/15246090260137572
J. Hootman, J. Sniezek, C. Helmick
OBJECTIVES To characterize the public health burden and impact of arthritis among women, document the growing interest in addressing arthritis as a public health problem, and review new national (Centers for Disease Control and Prevention [CDC]) and state arthritis programs. RESULTS Arthritis and other rheumatic diseases are a major public health problem, affecting nearly 27 million women in 1997 and accounting for 23.9 million ambulatory medical care visits and 451,000 hospitalizations among women in that year. Arthritis is also the leading cause of disability and is associated with considerable functional limitations. The 1999 National Arthritis Action Plan: A Public Health Strategy prompted first-time congressional funding to the CDC to monitor the burden of arthritis and to establish state arthritis prevention programs through cooperative agreements. The CDC's Arthritis Program also used this funding to build the public health science base, develop national health communications campaigns, foster partnerships, and initiate health systems change. CONCLUSIONS Arthritis in general and selected types, such as rheumatoid arthritis, systemic lupus erythmatosus (SLE), and fibromyalgia, disproportionately affect women. The CDC, state health departments, and their partners are working toward improving the quality of life for women affected by arthritis. Effective, evidence-based interventions, such as self-management education and physical activity programs, are currently available and can reduce pain, improve function, and delay disability, but they remain underused. Future research should focus on improving earlier diagnosis and increasing access to effective interventions.
{"title":"Women and arthritis: burden, impact and prevention programs.","authors":"J. Hootman, J. Sniezek, C. Helmick","doi":"10.1089/15246090260137572","DOIUrl":"https://doi.org/10.1089/15246090260137572","url":null,"abstract":"OBJECTIVES\u0000To characterize the public health burden and impact of arthritis among women, document the growing interest in addressing arthritis as a public health problem, and review new national (Centers for Disease Control and Prevention [CDC]) and state arthritis programs.\u0000\u0000\u0000RESULTS\u0000Arthritis and other rheumatic diseases are a major public health problem, affecting nearly 27 million women in 1997 and accounting for 23.9 million ambulatory medical care visits and 451,000 hospitalizations among women in that year. Arthritis is also the leading cause of disability and is associated with considerable functional limitations. The 1999 National Arthritis Action Plan: A Public Health Strategy prompted first-time congressional funding to the CDC to monitor the burden of arthritis and to establish state arthritis prevention programs through cooperative agreements. The CDC's Arthritis Program also used this funding to build the public health science base, develop national health communications campaigns, foster partnerships, and initiate health systems change.\u0000\u0000\u0000CONCLUSIONS\u0000Arthritis in general and selected types, such as rheumatoid arthritis, systemic lupus erythmatosus (SLE), and fibromyalgia, disproportionately affect women. The CDC, state health departments, and their partners are working toward improving the quality of life for women affected by arthritis. Effective, evidence-based interventions, such as self-management education and physical activity programs, are currently available and can reduce pain, improve function, and delay disability, but they remain underused. Future research should focus on improving earlier diagnosis and increasing access to effective interventions.","PeriodicalId":80044,"journal":{"name":"Journal of women's health & gender-based medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77549162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-06-01DOI: 10.1089/15246090260137617
J. Watson, I. Scarinci, R. Klesges, D. Slawson, B. Beech
OBJECTIVES Perceived discrimination and socioeconomic status (SES) have been found to be related to health problems. However, little is known about how SES and ethnicity relate to perception and responses to discrimination. This study examined the relationship between race and a set of SES indicators, perceived discrimination (race and gender), and responses to perceived discrimination among healthy women. METHODS The sample consisted of 460 women between the ages of 18 and 39 (194 black and 266 white). The independent variables included income, education, occupation, and race. The dependent variables included perceived discrimination (race/color and gender) and responses to unfair treatment. RESULTS Income and education were both directly related to perceived racial discrimination. However, the relationship between education and perceived discrimination was modified by race. For white women, only higher education was related to less perceived discrimination, and there was no significant difference across education levels for black women. Education was the only variable significantly associated with perceived gender discrimination (more highly educated women reported more discrimination). Occupation and race were both related to responses to perceived discrimination. Black women were significantly less likely to talk to someone when treated unfairly than white women (OR = 0.37, 95% confidence interval [CI] = 0.191, 0.716), and women in managerial/professional positions were significantly more likely to do something about being treated unfairly than women in service occupations (OR = 4.76, CI = 2.14, 10.61). CONCLUSIONS Our results suggest that both SES and race play important roles in women's perceptions of and responses to perceived discrimination.
{"title":"Race, socioeconomic status, and perceived discrimination among healthy women.","authors":"J. Watson, I. Scarinci, R. Klesges, D. Slawson, B. Beech","doi":"10.1089/15246090260137617","DOIUrl":"https://doi.org/10.1089/15246090260137617","url":null,"abstract":"OBJECTIVES\u0000Perceived discrimination and socioeconomic status (SES) have been found to be related to health problems. However, little is known about how SES and ethnicity relate to perception and responses to discrimination. This study examined the relationship between race and a set of SES indicators, perceived discrimination (race and gender), and responses to perceived discrimination among healthy women.\u0000\u0000\u0000METHODS\u0000The sample consisted of 460 women between the ages of 18 and 39 (194 black and 266 white). The independent variables included income, education, occupation, and race. The dependent variables included perceived discrimination (race/color and gender) and responses to unfair treatment.\u0000\u0000\u0000RESULTS\u0000Income and education were both directly related to perceived racial discrimination. However, the relationship between education and perceived discrimination was modified by race. For white women, only higher education was related to less perceived discrimination, and there was no significant difference across education levels for black women. Education was the only variable significantly associated with perceived gender discrimination (more highly educated women reported more discrimination). Occupation and race were both related to responses to perceived discrimination. Black women were significantly less likely to talk to someone when treated unfairly than white women (OR = 0.37, 95% confidence interval [CI] = 0.191, 0.716), and women in managerial/professional positions were significantly more likely to do something about being treated unfairly than women in service occupations (OR = 4.76, CI = 2.14, 10.61).\u0000\u0000\u0000CONCLUSIONS\u0000Our results suggest that both SES and race play important roles in women's perceptions of and responses to perceived discrimination.","PeriodicalId":80044,"journal":{"name":"Journal of women's health & gender-based medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80761079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-06-01DOI: 10.1089/15246090260137608
G. Wingood, R. DiClemente, K. Harrington, S. Davies
OBJECTIVES This study examines the association between African American adolescent females' body image and their sexual health. METHODS African American adolescent females (n = 522) completed a survey that assessed body image using a 7-item scale (alpha = 0.71) and a face-to-face interview that assessed sexual behaviors. RESULTS In logistic regression analyses, controlling for depression, self-esteem and body mass index (BMI), adolescents who were more dissatisfied with their body image were more likely to fear abandonment as a result of negotiating condom use (adjusted odds ratio [AOR] = 3.3, p = 0.02), more likely to perceive that they had fewer options for sexual partners (AOR = 2.4, p = 0.001), more likely to perceive themselves as having limited control in their sexual relationships (AOR = 2.0, p = 0.002), and more likely to worry about acquiring HIV(AOR = 1.5, p = 0.04). There was an association between having a greater dissatisfaction with one's body image and never using condoms during sexual intercourse in the past 30 days (AOR = 1.6, p = 0.04) and more likely to engage in unprotected vaginal sex in the prior 6 months (AOR = 1.6, p = 0.04). CONCLUSIONS Prior research has demonstrated an association between African American women's body image and greater obesity risk, lower self-esteem, and greater depression. The present study has shown an association between body image dissatisfaction and a range of sexual attitudes, beliefs, and behaviors. Women who are more dissatisfied with their body image may be at greater risk for unintended pregnancy, sexually transmitted infections (STIs), and HIV infection.
目的探讨非裔美国青少年女性身体形象与性健康的关系。方法对522名非裔美国青少年女性进行身体形象评估(alpha = 0.71)和性行为评估(面对面访谈)。RESULTSIn logistic回归分析,控制了抑郁,自尊和身体质量指数(BMI),青少年更不满意他们的身体形象更有可能害怕放弃谈判的结果使用避孕套(调整优势比(AOR) = 3.3, p = 0.02),更有可能认为他们有更少的性伴侣的选择(优势比= 2.4,p = 0.001),更有可能认为自己是有限的控制他们的性关系(优势比= 2.0,p = 0.002),更有可能担心感染艾滋病毒(AOR = 1.5, p = 0.04)。在过去30天内从未使用过避孕套的性行为中，对自己身体形象的不满意程度越高(AOR = 1.6, p = 0.04)，在过去6个月内进行无保护阴道性行为的可能性越大(AOR = 1.6, p = 0.04)。结论先前的研究表明，非裔美国女性的身体形象与更大的肥胖风险、更低的自尊和更大的抑郁之间存在关联。目前的研究表明，对身体形象的不满与一系列性态度、信仰和行为之间存在关联。对自己身体形象不满意的女性意外怀孕、性传播感染和艾滋病毒感染的风险更大。
{"title":"Body image and African American females' sexual health.","authors":"G. Wingood, R. DiClemente, K. Harrington, S. Davies","doi":"10.1089/15246090260137608","DOIUrl":"https://doi.org/10.1089/15246090260137608","url":null,"abstract":"OBJECTIVES\u0000This study examines the association between African American adolescent females' body image and their sexual health.\u0000\u0000\u0000METHODS\u0000African American adolescent females (n = 522) completed a survey that assessed body image using a 7-item scale (alpha = 0.71) and a face-to-face interview that assessed sexual behaviors.\u0000\u0000\u0000RESULTS\u0000In logistic regression analyses, controlling for depression, self-esteem and body mass index (BMI), adolescents who were more dissatisfied with their body image were more likely to fear abandonment as a result of negotiating condom use (adjusted odds ratio [AOR] = 3.3, p = 0.02), more likely to perceive that they had fewer options for sexual partners (AOR = 2.4, p = 0.001), more likely to perceive themselves as having limited control in their sexual relationships (AOR = 2.0, p = 0.002), and more likely to worry about acquiring HIV(AOR = 1.5, p = 0.04). There was an association between having a greater dissatisfaction with one's body image and never using condoms during sexual intercourse in the past 30 days (AOR = 1.6, p = 0.04) and more likely to engage in unprotected vaginal sex in the prior 6 months (AOR = 1.6, p = 0.04).\u0000\u0000\u0000CONCLUSIONS\u0000Prior research has demonstrated an association between African American women's body image and greater obesity risk, lower self-esteem, and greater depression. The present study has shown an association between body image dissatisfaction and a range of sexual attitudes, beliefs, and behaviors. Women who are more dissatisfied with their body image may be at greater risk for unintended pregnancy, sexually transmitted infections (STIs), and HIV infection.","PeriodicalId":80044,"journal":{"name":"Journal of women's health & gender-based medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89361462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-05-01DOI: 10.1089/152460902317586010
Y. Andejeski, I. Bisceglio, K. Dickersin, Jean E. S. Johnson, S. Robinson, H. Smith, F. Visco, I. Rich
OBJECTIVE To evaluate the impact of having breast cancer survivors with advocacy experience (consumers) participate as voting members of scientific review panels for proposals on breast cancer research. As major stakeholders, patients and other consumer advocates sought inclusion in all decision-making processes affecting funding of disease-targeted research. METHOD Cross-sectional analysis of assigned proposal scores ranging from 5.0 (acceptable) to 1.0 (outstanding); before (prepanel) and after (postpanel) opinion questionnaires. Forty-six panels reviewed 2206 proposals for the Fiscal Year 1995 Department of Defense (DOD) Breast Cancer Research Program. Analyses were limited to the 42 panels scheduled to meet on site and the 2190 proposals scored by both participant groups. There were 85 consumers and 638 scientists. The main outcome measures were proposal merit scores (raw, overall, and participant-specific means) and opinions concerning perceived benefits and drawbacks of consumer involvement. RESULTS In general, the voting patterns of consumers were similar to those of scientists. Final proposal scores were the same as those that would have been obtained without consumer voting for 76.2% of the proposals, more favorable for 15.2% of the proposals, and less favorable for 8.6% of the proposals. For all but 13 proposals, the difference was +/-0.1. Prepanel opinions regarding consumer involvement were generally positive. Prepanel and postpanel comparisons almost always showed that significantly greater proportions of participants had positive postpanel opinions than had negative postpanel opinions. Having consumers on review panels was reported to be beneficial (83.9% and 98.2% for scientists and consumers, respectively) and to not have drawbacks (74.7% and 87.3%, respectively). CONCLUSIONS Our results support continued participation of consumers in our peer review process. The DOD program can serve as a model for other research programs considering consumer involvement.
{"title":"Quantitative impact of including consumers in the scientific review of breast cancer research proposals.","authors":"Y. Andejeski, I. Bisceglio, K. Dickersin, Jean E. S. Johnson, S. Robinson, H. Smith, F. Visco, I. Rich","doi":"10.1089/152460902317586010","DOIUrl":"https://doi.org/10.1089/152460902317586010","url":null,"abstract":"OBJECTIVE\u0000To evaluate the impact of having breast cancer survivors with advocacy experience (consumers) participate as voting members of scientific review panels for proposals on breast cancer research. As major stakeholders, patients and other consumer advocates sought inclusion in all decision-making processes affecting funding of disease-targeted research.\u0000\u0000\u0000METHOD\u0000Cross-sectional analysis of assigned proposal scores ranging from 5.0 (acceptable) to 1.0 (outstanding); before (prepanel) and after (postpanel) opinion questionnaires. Forty-six panels reviewed 2206 proposals for the Fiscal Year 1995 Department of Defense (DOD) Breast Cancer Research Program. Analyses were limited to the 42 panels scheduled to meet on site and the 2190 proposals scored by both participant groups. There were 85 consumers and 638 scientists. The main outcome measures were proposal merit scores (raw, overall, and participant-specific means) and opinions concerning perceived benefits and drawbacks of consumer involvement.\u0000\u0000\u0000RESULTS\u0000In general, the voting patterns of consumers were similar to those of scientists. Final proposal scores were the same as those that would have been obtained without consumer voting for 76.2% of the proposals, more favorable for 15.2% of the proposals, and less favorable for 8.6% of the proposals. For all but 13 proposals, the difference was +/-0.1. Prepanel opinions regarding consumer involvement were generally positive. Prepanel and postpanel comparisons almost always showed that significantly greater proportions of participants had positive postpanel opinions than had negative postpanel opinions. Having consumers on review panels was reported to be beneficial (83.9% and 98.2% for scientists and consumers, respectively) and to not have drawbacks (74.7% and 87.3%, respectively).\u0000\u0000\u0000CONCLUSIONS\u0000Our results support continued participation of consumers in our peer review process. The DOD program can serve as a model for other research programs considering consumer involvement.","PeriodicalId":80044,"journal":{"name":"Journal of women's health & gender-based medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83095185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2002-05-01DOI: 10.1089/152460902317586001
R. Basson, Rosemary McInnes, Mike D. Smith, Gemma Hodgson, N. Koppiker
OBJECTIVE Sildenafil citrate (Viagra Pfizer, New York, NY) is indicated for the treatment of erectile dysfunction in men. The nitric oxide-cyclic guanosine monophosphate pathway (NO-cGMP) involved in penile erection and enhanced by sildenafil may also play a role in some components of the female sexual arousal response. The efficacy and safety of sildenafil were evaluated in estrogenized and estrogen-deficient women with sexual dysfunction that included female sexual arousal disorder (FSAD). METHODS Patients were randomized to receive 10-100 mg sildenafil or matching placebo. To assess efficacy, patients completed two global efficacy questions (GEQ), the Life Satisfaction Checklist (LSC), an event log of sexual activity, and a 31-item sexual function questionnaire (SFQ). To assess safety, adverse event (AE) data were recorded. RESULTS A total of 577 estrogenized and 204 estrogen-deficient women were randomized to treatment. All were diagnosed with FSAD, but it was the primary presenting symptom in only 46% and 50% of women, respectively. Differences in efficacy between sildenafil and placebo were not significant for any patient or partner end points (e.g., the two GEQ, the sexual event logs, the LSC, and the SFQ). The main AE were headache, flushing, rhinitis, nausea, visual disturbances, and dyspepsia, which were generally mild to moderate in nature. CONCLUSIONS Any genital physiological effect of sildenafil was not perceived as improving the sexual response in estrogenized or estrogen-deficient women with a broad spectrum of sexual dysfunction that included FSAD. Whether more specific subgroups of women with FSAD could potentially benefit from treatment with sildenafil is an area for future research.
{"title":"Efficacy and safety of sildenafil citrate in women with sexual dysfunction associated with female sexual arousal disorder.","authors":"R. Basson, Rosemary McInnes, Mike D. Smith, Gemma Hodgson, N. Koppiker","doi":"10.1089/152460902317586001","DOIUrl":"https://doi.org/10.1089/152460902317586001","url":null,"abstract":"OBJECTIVE\u0000Sildenafil citrate (Viagra Pfizer, New York, NY) is indicated for the treatment of erectile dysfunction in men. The nitric oxide-cyclic guanosine monophosphate pathway (NO-cGMP) involved in penile erection and enhanced by sildenafil may also play a role in some components of the female sexual arousal response. The efficacy and safety of sildenafil were evaluated in estrogenized and estrogen-deficient women with sexual dysfunction that included female sexual arousal disorder (FSAD).\u0000\u0000\u0000METHODS\u0000Patients were randomized to receive 10-100 mg sildenafil or matching placebo. To assess efficacy, patients completed two global efficacy questions (GEQ), the Life Satisfaction Checklist (LSC), an event log of sexual activity, and a 31-item sexual function questionnaire (SFQ). To assess safety, adverse event (AE) data were recorded.\u0000\u0000\u0000RESULTS\u0000A total of 577 estrogenized and 204 estrogen-deficient women were randomized to treatment. All were diagnosed with FSAD, but it was the primary presenting symptom in only 46% and 50% of women, respectively. Differences in efficacy between sildenafil and placebo were not significant for any patient or partner end points (e.g., the two GEQ, the sexual event logs, the LSC, and the SFQ). The main AE were headache, flushing, rhinitis, nausea, visual disturbances, and dyspepsia, which were generally mild to moderate in nature.\u0000\u0000\u0000CONCLUSIONS\u0000Any genital physiological effect of sildenafil was not perceived as improving the sexual response in estrogenized or estrogen-deficient women with a broad spectrum of sexual dysfunction that included FSAD. Whether more specific subgroups of women with FSAD could potentially benefit from treatment with sildenafil is an area for future research.","PeriodicalId":80044,"journal":{"name":"Journal of women's health & gender-based medicine","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2002-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76355448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：